Shattuck Labs (STTK) has provided an update.
Shattuck Labs, Inc. has announced the appointment of Dr. Kate Sasser and Dr. Clay Siegall to its Board of Directors, expanding the board’s expertise in the biotechnology and pharmaceutical sectors. Dr. Sasser brings a wealth of experience from her tenure at Tempus AI and Genmab A/S, alongside her scientific roles at Johnson and Johnson. Dr. Siegall, with a distinguished career including leadership at Immunome, Inc. and Seagen Inc., adds significant executive experience to the board. Their appointments are part of the company’s strategic positioning for future growth, reflecting a commitment to strong governance and innovative leadership in the healthcare technology arena.
Learn more about STTK stock on TipRanks’ Stock Analysis page.
